All News
RheumNow Podcast – JAK Inhibitor Warnings from the FDA
FDA JAK inhibitor warnings and what it means (also: what do you think?); other news released this week; and, two questions submitted from listeners. Dr. Cush discusses this and more in this week's podcast.
Read Article
MMWR: COVID-19–hospitalization rates in kids & adolescents rose 5-fold late June–mid-Aug 2021 (w/ rise of Delta variant). Hospitalization rates were 10 times higher among unvaccinated than fully vaccinated adolescents. https://t.co/Qt5lj3Ycxb https://t.co/p2e0KoiAXr
Links:
Dr. John Cush RheumNow ( View Tweet)
#Fatigue in the ARCTIC study studied using a 0-100 VAS over 24 mos. Baseline median fatigue 37mm & DAS=3.4. Fatigue declined 69% to 38% @24 mos. Predictors: low dz activity & high pt global. No remission at 6 mos assoc w/ fatigue at 24 mos https://t.co/NDk8fvr7Mq
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:
Belimumab in Pregnancy? a study of 13 pregnancies in 13 pts, mean age 38 yrs.. There were 11 live births, 1 case omphalitis (recovered w Abx) . No fetal anomalies found. 6 pts (46%) w/ Hx of recurrent pregnancy loss, four had live births on BEL https://t.co/FJJhepa25M
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA JAKi Warnings, 2nd Panel of rheumatologists weigh in on this. Drs. Cush, Dao, Tate, Sparks, Shergy. https://t.co/eETzP8DspC via @YouTube #RheumNow @KDAO2011 @uptoTate @jeffsparks @WilliamShergy https://t.co/iqxFQjJQ0l
Links:
Dr. John Cush RheumNow ( View Tweet)
Do you subscribe to our weekly podcast? It’s available wherever you download your podcasts—just search RheumNow. And, of course, find it on the site each Friday!
https://t.co/wjBWCrKL34 https://t.co/MZzpNIpTv1
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:
Using inpatient hospital records of 1.9 million SLE pts, the mortality of hospitalized #SLE changed little from 2006-2016;mortality dropped from 2.2% to 1.5% - with most of this decline between 2006-‘08 and no change since. Racial disparities seen. https://t.co/UUsJYFxQS4
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI
Expert Panel: Initial Views on FDA Warnings for JAK Inhibitors
https://t.co/omeZyprT96 https://t.co/UGBlb9m5bS
Links:
Dr. John Cush RheumNow ( View Tweet)
Highly allergic can safely get the COVID Vax. Israeli study of 8102 pts w/ allergies recv Pfizer mRNA vax - 429 were highly allergic-->98% of the highly allergic had no allergic rxns, 1% mild allergic resp & 3 anaphylactic rxns Rx w/ EPI, none hospitalized https://t.co/ATYs5R5AQC https://t.co/owNEACH1pe
Links:
Dr. John Cush RheumNow ( View Tweet)
New podcast available! Download wherever you get your podcasts.
https://t.co/4jTBhYDzRn https://t.co/DUWVD89JJ5
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:
FDA slaps new BOXED warning revision on ALL JAK inhibitors (Xeljanz, Olumiant, Rinvoq) after final revew of the Pfizer Oral Surveillance study. New warnings for incr risk of MI, CVA, VTE, lymphoma & death see w/ BOTH dose of tofacitinib. https://t.co/tvTv40oy59
Links:
Dr. John Cush RheumNow ( View Tweet)
500 Turkish pts from 4 pediatric rheum clinics. Oligoart. JIA (oJIA) was most common (39%), then enthesitisJIA (ERA-23%), RF neg polyarthritis (16%), RF+ poly (2.2%), Systemic JIA (16%), juvenile PsA (5.2%). Uveitis most common in oJIA (13%), then ERA (5%) https://t.co/a7O1RBM1xJ https://t.co/woSafvVsmA
Links:
Dr. John Cush RheumNow ( View Tweet)
Not All Immunosuppression Alters Vaccine Immunogenicity
https://t.co/I9sShpMLBO https://t.co/oz9Qp1HM1e
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA JAKi Warnings, 2nd Panel of rheumatologists weigh in on this. Drs. Cush, Dao, Tate, Sparks, Shergy. https://t.co/0WqeV6jKex via @YouTube #RheumNow @KDAO2011 @uptoTate @jeffsparks @WilliamShergy
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA JAK inhibitor warnings and what it means (also: what do you think?); other news released this week; and, two questions submitted from listeners. Dr. Cush discusses this and more in this week's podcast.
https://t.co/4jTBhYDzRn https://t.co/lMpl2IOeXe
Links:
Dr. John Cush RheumNow ( View Tweet)
Expert Panel: Initial Views on FDA Warnings for JAK Inhibitors
https://t.co/omeZyprT96 https://t.co/zXlGpEK6cC
Links:
Dr. John Cush RheumNow ( View Tweet)
FORWARD prospective registry showed Obesity to be associated with a substantially higher risk of incident chronic opioid use (HR adj 1.74). Approximately 1 in 4 cases of incident strong opioid use can be attributable to obesity ((HRadj 2.11) https://t.co/R0KhH4b05g https://t.co/HGHeqh4B0c
Links:
Dr. John Cush RheumNow ( View Tweet)
PhIII trial of Baricitinib vs placebo in hospitalized COVID-19 pts (91% steroids, 13% remdesivir). While no diff (28 vs 30%) in primary outcome (O2, ventilation, death). BARI had signif better Mortality @28d (8 vs 13%) & 60d (10 vs 15%) w/ no incr in VTE https://t.co/AjoRgEKW8G
Links:
Dr. John Cush RheumNow ( View Tweet)
Highly allergic can safely get the COVID Vax. Israeli study of 8102 pts w/ allergies recv Pfizer mRNA vax - 429 were highly allergic-->98% of the highly allergic had no allergic rxns, 1% mild allergic resp & 3 anaphylactic rxns Rx w/ EPI, none hospitalized https://t.co/ATYs5R5AQC https://t.co/RoYU2vVLl2
Links:
Dr. John Cush RheumNow ( View Tweet)
Did you know that we have large library of downloads available for use in education? Head to RheumNow and download today.
https://t.co/CEbS8eDs1j https://t.co/VTJWYUrm8U
Links:
Dr. John Cush RheumNow ( View Tweet)